<DOC>
	<DOCNO>NCT02706080</DOCNO>
	<brief_summary>Antithrombotics antiplatelet agent , vitamin K antagonist ( VKA ) , heparin related substance , new oral anticoagulant prescribe arterial disease , especially secondary prevention embolic disease carrier patient heart valves patient fibrillation atrial , venous disease , prevention treatment . The prescription treatment increase especially old patient associate many comorbidities . Today , estimate number 900 000 patient anti-vitamin K France , 1.5 million patient antiplatelet agent . Venous thromboembolism ( VTE ) common general population annual incidence 10-18 case per 10 000 . The severe form VTE represent pulmonary embolism third case . Even large literature allow high grade recommendation many area , still gray area regard long-term outcome , early evolution tolerance treatment , include long-term recurrence , incidence embolic sequelae post-embolic pulmonary hypertension association cardiovascular arterial accident ( acute Coronary Syndrome , Stroke , arterial disease Lower Extremities ... ) . The major risk antithrombotic bleeding term morbidity mortality . Despite risk , little study focus exact epidemiology bleed associate use antithrombotic . If frequency hemorrhagic stroke low , population particularly risk bleed represent majority serious bleed event VKA anti-platelet . However , VKA antiplatelet agent first provider hemorrhagic serious side effect drug look national international study iatrogenic top gastrointestinal bleeding intracerebral hemorrhage ( mortality 10 15 % ) . Moreover recent arrival new oral anticoagulant ( Apixaban rivaroxaban , dabigatran ... ) profoundly change management venous thromboembolism cardioembolic event . Because risk-benefit , simplicity convenience prescription , number patient treat new anticoagulant rise rapidly . In addition , many patient deem `` fragile '' treat VKA , treat treatment . These new anti-Xa anti-IIa anticoagulant already market . They advantage VKA : oral way , pharmacokinetic characteristic , absence biological monitoring , chemical synthesis ... . If possible today give advantage one molecule , choice direct pharmacokinetic characteristic , half life , method disposal also patient co-morbidities . Although biological test currently available monitoring product , therapeutic solution severe bleed exist : indeed antidote , though issue find balance increase therapeutic benefit bleeding risk optimization . But hemorrhagic stroke serious complication oral anticoagulant therapy , substantial documentation event occur VKA little data occur new oral anticoagulant ( Apixaban rivaroxaban , dabigatran ... ) .</brief_summary>
	<brief_title>Registry Patient With Antithrombotic Agents Admitted Emergency Department</brief_title>
	<detailed_description>We propose realize single-center prospective registry patient Antithrombotic agent come emergency unit reason .</detailed_description>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Fibrinolytic Agents</mesh_term>
	<criteria>Age 18 year Patient antithrombotic agent come emergency unit reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Antithrombotic agent</keyword>
	<keyword>VKA</keyword>
	<keyword>Direct Oral Anticoagulant</keyword>
	<keyword>Antiplatelet</keyword>
	<keyword>Bleeding</keyword>
	<keyword>Emergency</keyword>
</DOC>